Mostrar el registro sencillo del ítem
dc.contributor.author | Sánchez-Alonso, Santiago | |
dc.contributor.author | Alcaraz-Serna, Ana | |
dc.contributor.author | Sanchez-Madrid, Francisco | |
dc.contributor.author | Alfranca, Arantzazu | |
dc.date.accessioned | 2019-02-06T08:47:45Z | |
dc.date.available | 2019-02-06T08:47:45Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Front Immunol. 2018; 9(15):2799 | es_ES |
dc.identifier.issn | 1664-3224 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/7128 | |
dc.description.abstract | Myocardial ischemia-related disorders constitute a major health problem, being a leading cause of death in the world. Upon ischemia, tissue remodeling processes come into play, comprising a series of inter-dependent stages, including inflammation, cell proliferation and repair. Neovessel formation during late phases of remodeling provides oxygen supply, together with cellular and soluble components necessary for an efficient myocardial reconstruction. Immune system plays a central role in processes aimed at repairing ischemic myocardium, mainly in inflammatory and angiogenesis phases. In addition to cellular components and soluble mediators as chemokines and cytokines, the immune system acts in a paracrine fashion through small extracellular vesicles (EVs) release. These vesicular structures participate in multiple biological processes, and transmit information through bioactive cargoes from one cell to another. Cell therapy has been employed in an attempt to improve the outcome of these patients, through the promotion of tissue regeneration and angiogenesis. However, clinical trials have shown variable results, which put into question the actual applicability of cell-based therapies. Paracrine factors secreted by engrafted cells partially mediate tissue repair, and this knowledge has led to the hypothesis that small EVs may become a useful tool for cell-free myocardial infarction therapy. Current small EVs engineering strategies allow delivery of specific content to selected cell types, thus revealing the singular properties of these vesicles for myocardial ischemia treatment. | es_ES |
dc.description.sponsorship | This work was supported by grants to AA-S (FIS PI15/01491) and to FS-M (grants SAF2014-55579-R and SAF2017-82886-R to FS-M), BIOIMID PIE13/041 and CIBER CARDIOVASCULAR from the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria del Instituto de Salud Carlos III with co-funding from the Fondo Europeo de Desarrollo Regional; FEDER), Programa de Actividades en Biomedicina de la Comunidad de Madrid-B2017/BMD-3671-INFLAMUNE to FS-M, and ERC2011-AdG294340-GENTRIS to FS-M, and Fundació La Marató TV3 (20152330 31). The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the Spanish Ministry of Economy and Competitiveness (MINECO) and the ProCNIC Foundation and is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0505). | es_ES |
dc.language.iso | eng | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-sa/4.0/ | * |
dc.subject | Angiogenesis | es_ES |
dc.subject | Immune system | es_ES |
dc.subject | Myocardial infarction | es_ES |
dc.subject | Small EVs | es_ES |
dc.subject | Tissue remodeling | es_ES |
dc.title | Extracellular Vesicle-Mediated Immune Regulation of Tissue Remodeling and Angiogenesis After Myocardial Infarction | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 30555478 | es_ES |
dc.format.volume | 9 | es_ES |
dc.format.page | 2799 | es_ES |
dc.identifier.doi | 10.3389/fimmu.2018.02799 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Centro de Investigación Biomedica en Red - CIBER | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.contributor.funder | Comunidad de Madrid (España) | |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.contributor.funder | Fundación ProCNIC | |
dc.contributor.funder | Unión Europea. Comisión Europea | |
dc.contributor.funder | Unión Europea. Comisión Europea. European Research Council (ERC) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1664-3224 | es_ES |
dc.identifier.journal | Frontiers in immunology | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Comunicación Intercelular en la Respuesta Inflamatoria | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SEV-2015-0505 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/294340/EU | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PIE13/041 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI15/01491 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2014-55579-R | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2017-82886-R | es_ES |
dc.rights.accessRights | open access | es_ES |